{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-026904","form_type":"8-K","ticker":"LYEL","cik":"0001806952","company_name":"Lyell Immunopharma, Inc.","filed_at":"2022-10-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.226001+00:00","generated_at":"2026-06-23T01:42:07.946156+00:00","sec_items":["1.02"],"event_type":"other_material","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"GSK terminates collaboration with Lyell; NY-ESO-1 programs discontinued","bullets":["GSK provided termination notice Oct 24, 2022, effective Dec 24, 2022; ends development of LYL132 and LYL331 incorporating Lyell's technologies.","Termination follows GSK's strategic review after lete-cel NSCLC data; not based on safety/efficacy of Lyell's programs.","Lyell discontinuing further work on these programs; minimal operational impact as GSK ran them; no patients treated with LYL132.","Cash, cash equivalents and marketable securities expected to fund working capital into 2025; Glaxo Group remains significant stockholder.","Lyell received $250M upfront/equity in 2019 collaboration; would have been eligible for milestones and royalties."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-026904","json":"https://secwatch.observer/filing/0001628280-22-026904.json","markdown":"https://secwatch.observer/filing/0001628280-22-026904.md","text":"https://secwatch.observer/filing/0001628280-22-026904.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1806952/000162828022026904/0001628280-22-026904-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1806952/000162828022026904/lyel-20221024.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T01:42:07.946156+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}